{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"PE-PE","nct_id":"NCT05578664","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pe-pe-nct05578664. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PE-PE","arms":[{"description":"Pembrolizumab will be administered at flat dose of 400 mg IV every six weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RadioTherapy, RT) from day 21 of cycle 1 to day 42 of cycle 1.","label":"ARM A","type":"EXPERIMENTAL"},{"description":"Local therapy alone (tumor resection or definitive RadioTherapy, RT) within 42 days from randomization.","label":"ARM B","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-10","type":"ESTIMATED"},"conditions":["Oligometastatic Renal Cell Carcinoma"],"enrollment":{"count":81,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab injection plus metastasis directed treatment (surgery or RT)","otherNames":[],"type":"DRUG"},{"name":"Tumor resection or RT","otherNames":[],"type":"OTHER"}],"last_update":"2023-08-30","lead_sponsor":"Consorzio Oncotech","official_title":"Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer. (The PE-PE Study).","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2024-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Relapsed Free Survival (RFS)","timeFrame":"24 months"}],"references":[],"start_date":{"date":"2023-03-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer","url":"https://clinicaltrials.gov/study/NCT05578664"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pe-pe-nct05578664"}